Photoimmunotherapy with surgical navigation and computed tomography guidance for recurrent maxillary sinus carcinoma

Published:September 18, 2022DOI:


      Photoimmunotherapy (PIT) using lasers to target treatment areas is effective for unresectable locally advanced or unresectable locoregionally recurrent head and neck cancer; however, there are only two devices to target the treatment area. One illuminates tumour tissue through a needle, and the other illuminates tumour tissue superficially. Treating lesions surrounded by bone, such as in maxillary sinus cancer, is difficult. We report the first case of PIT for unresectable recurrent maxillary sinus cancer employing surgical navigation and computed tomography guidance in a 56-year-old man. Although he underwent concurrent chemoradiotherapy for cT4bN0M0 maxillary sinus cancer, the tumour recurred at the primary site 6 months post treatment. Chemotherapy was performed for approximately 1 year; however, the tumour progressed. The tumour involved the anterior wall of the maxillary sinus and caused bone destruction; thus, we believed that PIT with a needle device was possible if the puncture was carefully performed. We used a surgical navigation system for neurosurgery and computed tomography guidance to ensure that intraoperative punctures were accurately performed. The operation time was 1 h 52 min and the treatment was completed as planned. Tumour necrosis and volume reduction were obtained with no severe adverse events, which reduced the patient's pain.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chow LQM.
        Head and neck cancer.
        N Engl J Med. 2020; 382: 60-72
        • Bray F
        • Ferlay J
        • Soerjomataram I
        • Siegel RL
        • Torre LA
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Khuri FR
        • Shin DM
        • Glisson BS
        • Lippman SM
        • Hong WK.
        Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
        Semin Oncol. 2020; 27: 25-33
        • Lee YG
        • Kang EJ
        • Yun HJ
        • Keam B
        • Choi JH
        • Kim JS
        • et al.
        Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
        BMC Cancer. 2020; 20: 813
        • Pignon JP
        • A le Maître
        • Maillard E
        • Bourhis J.
        MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
        Radiother Oncol. 2009; 92: 4-14
        • Muzaffar J
        • Bari S
        • Kirtane K
        • Chung CH.
        Recent advances and future directions in clinical management of head and neck squamous cell carcinoma.
        Cancers. 2021; 13: 338
        • Hamoir M
        • Holvoet E
        • Ambroise J
        • Lengelé B
        • Schmitz S.
        Salvage surgery in recurrent head and neck squamous cell carcinoma: oncologic outcome and predictors of disease free survival.
        Oral Oncol. 2017; 67: 1-9
        • Kim YS.
        Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence.
        Radiat Oncol J. 2017; 35: 1-15
        • Brockstein BE
        • Vokes EE.
        Treatment of metastatic and recurrent head and neck cancer.
        UpToDate, Waltham, MA.30 March 2022 (UpToDate, Post TW (editor)Accessed on)
        • Oliveira TB
        • Mesía R
        • Falco A
        • Hsieh JC
        • Yokota T
        • Saada-Bouzid E
        • et al.
        Defining the needs of patients with recurrent and/or metastatic head and neck cancer: an expert opinion.
        Crit Rev Oncol Hematol. 2021; 157103200
        • Kobayashi H
        • Furusawa A
        • Rosenberg A
        • Choyke PL.
        Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity.
        Int Immunol. 2021; 33: 7-15
        • Mitsunaga M
        • Ogawa M
        • Kosaka N
        • Rosenblum LT
        • Choyke PL
        • Kobayashi H.
        Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.
        Nat Med. 2011; 17: 1685-1691
        • Ogawa M
        • Tomita Y
        • Nakamura Y
        • Lee MJ
        • Lee S
        • Tomita S
        • et al.
        Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
        Oncotarget. 2017; 8: 10425-10436
        • Matsushita S
        • Tachibana K
        • Kusakabe T
        • Hirayama R
        • Tsutsumi Y
        • Kondoh M.
        Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval.
        Clin Transl Sci. 2021; 14: 806-811
        • Tahara M
        • Okano S
        • Enokida T
        • Ueda Y
        • Fujisawa T
        • Shinozaki T
        • et al.
        A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma.
        Int J Clin Oncol. 2021; 26: 1812-1821
        • Strauss G
        • Koulechov K
        • Röttger S
        • Bahner J
        • Trantakis C
        • Hofer M
        • et al.
        Evaluation of a navigation system for ENT with surgical efficiency criteria.
        Laryngoscope. 2006; 116: 564-572
        • Poulou LS
        • Tsagouli P
        • Ziakas PD
        • Politi D
        • Trigidou R
        • Thanos L.
        Computed tomography-guided needle aspiration and biopsy of pulmonary lesions: a single-center experience in 1000 patients.
        Acta Radiol. 2013; 54: 640-645
        • DelGaudio JM
        • Dillard DG
        • Albritton FD
        • Hudgins P
        • Wallace VC
        • Lewis MM.
        Computed tomography–guided needle biopsy of head and neck lesions.
        Arch Otolaryngol Head Neck Surg. 2000; 126: 366-370
        • Eisenhauer EA
        • Therasse P
        • Bogaerts J
        • Schwartz LH
        • Sargent D
        • Ford R
        • Dancey J
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Leemans CR
        • Braakhuis BJ
        • Brakenhoff RH.
        The molecular biology of head and neck cancer.
        Nat Rev Cancer. 2011; 11: 9-22
        • Okamoto I
        • Okada T
        • Tokashiki K
        • Tsukahara K.
        A case treated with photoimmunotherapy under a navigation system for recurrent lesions of the lateral pterygoid muscle.
        In Vivo. 2022; 36: 1035-1040